In detail, they showed that patients who developed severe CRS [grade ≥ 4, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0)] exhibited significantly elevated levels of Ang-2, Ang-2:Ang-1 ratio, and VWF at the peak of blood CAR-T expansion, as compared to both subjects without CRS (p = 0.02, p < 0.0001, p = 0.01, respectively) and patients with mild CRS (grade 1–3) (p = 0.002, p = 0.0007, p = 0.002, respectively) [49]. The gene discussed is ANGPT2; the disease is congenital rubella syndrome.